Skip Navigation

This Article
Right arrow Print PDF (2812K)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (109)
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Broggini, M.
Right arrow Articles by Mantovani, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Broggini, M.
Right arrow Articles by Mantovani, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 1989, Vol. 17, No. 3 1051-1059
© 1989

MOLECULAR BIOLOGY

Distamycins inhibit the binding of OTF-1 and NFE-1 transfactors to their conserved DNA elements

Massimo Broggini, Mauro Ponti, Sergio Ottolenghi1, Maurizio D'Incalci*, Nicola Mongelli2 and Roberto Mantovani1

Laboratory of Cancer Chemotherapy, Istituto di Ricerche Farmacologiche ‘Mario Negri’ Via Eritrea 62, 20157 Milan 1Dipartimento di Genetica e di Biologia dei Microorganismi, Umversità di Milano Milan 2Laboratorio di Recerca e Sviluppo, Farmitalia Carlo Erba Milan, Italy

*To whom correspondence should be addressed

Received October 25, 1988. Revised January 5, 1989. Accepted January 5, 1989.

We investigated the effects of the antiviral agent distamycin A and of a distamycin derivative (FCE 24517) which possesses antineoplastic activity on the binding of some regulatory proteins to DNA. Both compounds inhibited the binding to DNA of the ubiquitous octamer binding factor OTF 1 and of the erythroid specific GATAAG protein (NFE 1). This was shown using the electrophoretic mobility shift assay on a DNA fragment of human {gamma}-globin gene promoter (–156 to –201), on the same fragment with a point mutation (T to C mutation) known to have an increased affinity of binding for NFE 1, on a DNA fragment of human histone H2B promoter and on a DNA fragment of mouse {alpha}1 globin promoter. The ability of distamycin or of FCE 24517 to inhibit the binding was specific for AT-rich sequences since neither drug inhibited the binding of nuclear protein factors to the sequence CCACACCC of the human ß globin gene. Binding to DNA was investigated by evaluating the drugs' ability to protect selected sequences from DNase I digestion (DNase footprinting). Distamycins binding was highly preferential for DNA sequences containing stretches of AT. These studies indicate that chemicals which have a high degree of DNA sequence-specific binding can selectively inhibit the binding of regulatory proteins to DNA. These effects might be responsible for modification of the transcripion of specific genes and might to some extent account for these drugs' antiviral and antineoplastic activities. This approach offers potential for the investigation of new such drugs.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
M. V. Karamouzis, V. G. Gorgoulis, and A. G. Papavassiliou
Transcription Factors and Neoplasia: Vistas in Novel Drug Design
Clin. Cancer Res., May 1, 2002; 8(5): 949 - 961.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. Gambari, G. Feriotto, C. Rutigliano, N. Bianchi, and C. Mischiati
Biospecific Interaction Analysis (BIA) of Low-Molecular Weight DNA-Binding Drugs
J. Pharmacol. Exp. Ther., July 1, 2000; 294(1): 370 - 377.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Minuzzo, S. Marchini, M. Broggini, G. Faircloth, M. D'Incalci, and R. Mantovani
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
PNAS, June 6, 2000; 97(12): 6780 - 6784.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S.-Y. Chiang, J. J. Welch, F. J. Rauscher III, and T. A. Beerman
Effect of DNA-binding Drugs on Early Growth Response Factor-1 and TATA Box-binding Protein Complex Formation with the Herpes Simplex Virus Latency Promoter
J. Biol. Chem., September 27, 1996; 271(39): 23999 - 24004.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
J Carmichael
Current Issues in Cancer: Cancer chemotherapy: identifying novel anticancer drugs
BMJ, May 14, 1994; 308(6939): 1288 - 1290.
[Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.